Dupilumab in children and adolescents with atopic dermatitis, a 52-week real-life experience: first report in Colombia
DOI:
https://doi.org/10.29176/2590843X.1743Keywords:
Biológico, Dermatitis atópica, Dupilumab, EczemaAbstract
Atopic dermatitis (AD) is a chronic inflammatory disease characterized by relapsing eczema and pruritus. Recently, dupilumab has shown to be safe and improve symptoms of moderate to severe AD in adolescents up to 52 weeks, however, very few Latin American patients were included, so comprehensive real-world data is needed. To our knowledge, there are no real-world studies published in this ethnicity regarding long-term treatment with Dupilumab for AD in adolescents.
Author Biographies
Daniela Meléndrez Vásquez, Hospital Militar Central
Hospital Militar Central, Bogotá, Colombia.
María Fernanda Ordoñez-Rubiano, Hospital Militar Central
Hospital Militar Central, Bogotá, Colombia.
Daniela Marín-Acevedo, Hospital Militar Central, Bogotá, Colombia
Hospital Militar Central, Bogotá, Colombia.
References
Licari A, Castagnoli R, Marseglia A, et al. Dupilumab to treat type 2 Inflammatory Diseases in Children and Adolescents. Paediatr Drugs. 2020;22(3):295-310. DOI: https://doi.org/10.1007/s40272-020-00387-2
Cork MJ, Thaçi D, Eichenfield LF, et al. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension. Br J Dermatol. 2020;182:85-96. DOI: https://doi.org/10.1111/bjd.18476
Blauvelt A, Guttman-Yassky E, Paller AS, et al. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE). Am J Clin Dermatol. 2022;23;365–383. DOI: https://doi.org/10.1007/s40257-022-00683-2
Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156:44-56. DOI: https://doi.org/10.1001/jamadermatol.2019.3336
Stingeni L, Bianchi L, Antonelli E, et al. Dupilumab for Atopic Dermatitis of the Adolescence Study Group. Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience. J Eur Acad Dermatol Venereol. 2022;12. doi: https://doi.org/10.1111/jdv.18141. Epub ahead of print.
How to Cite
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Daniela Meléndrez Vásquez, María Fernanda Ordoñez-Rubiano, Daniela Marín-Acevedo
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
